NasdaqCM - Nasdaq Real Time Price • USD
Agenus Inc. (AGEN)
As of 11:57 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 3 | 4 | 5 |
| Avg. Estimate | -2.83 | -2.71 | -6.1 | -12.91 |
| Low Estimate | -4.2 | -4.13 | -17.02 | -21.55 |
| High Estimate | -1.6 | -1.8 | 6.4 | -7.42 |
| Year Ago EPS | -4.4 | -4 | -13.8 | -6.1 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 4 | 3 | 5 |
| Avg. Estimate | 39.27M | 66.56M | 157.35M | 199.22M |
| Low Estimate | 34M | 34M | 135.8M | 144.4M |
| High Estimate | 46.3M | 148.36M | 186.24M | 251.5M |
| Year Ago Sales | 22.9M | 24.12M | 156.31M | 157.35M |
| Sales Growth (year/est) | 71.50% | 176.00% | 0.70% | 26.60% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -4.2 | -3.97 | -3.84 | -1.05 |
| EPS Actual | -4.4 | -4 | -3.2 | -2.6 |
| Difference | -0.2 | -0.03 | 0.64 | -1.55 |
| Surprise % | -4.80% | -0.80% | 16.70% | -147.60% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -2.83 | -2.71 | -6.1 | -12.91 |
| 7 Days Ago | -0.15 | -0.08 | -0.32 | -0.69 |
| 30 Days Ago | -0.15 | -0.09 | -0.41 | -0.69 |
| 60 Days Ago | -0.15 | -0.15 | -0.37 | -0.67 |
| 90 Days Ago | -0.15 | -0.15 | -0.37 | -0.67 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 2 | 1 | 2 |
| Up Last 30 Days | 1 | 2 | 1 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | 1 | -- |
Growth Estimates
| CURRENCY IN USD | AGEN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 35.70% | -- | -- | 0.80% |
| Next Qtr. | 32.20% | -- | -- | 9.60% |
| Current Year | 55.80% | -- | -- | 4.50% |
| Next Year | -111.60% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | B. Riley Securities: Buy to Buy | 3/18/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/14/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/8/2023 |
| Reiterates | EF Hutton: Buy to Buy | 7/3/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 7/3/2023 |
| Initiated | Baird: Outperform | 6/6/2023 |
Related Tickers
IBRX ImmunityBio, Inc.
5.11
+3.97%
JANX Janux Therapeutics, Inc.
47.73
-2.30%
BHVN Biohaven Ltd.
40.48
-3.98%
MRNS Marinus Pharmaceuticals, Inc.
1.4805
+5.00%
GERN Geron Corporation
3.7750
+1.21%
VERA Vera Therapeutics, Inc.
37.55
-4.89%
VNDA Vanda Pharmaceuticals Inc.
5.01
+0.80%
INKT MiNK Therapeutics, Inc.
0.8800
+0.95%
PXMD PaxMedica, Inc.
0.7700
+0.91%
ALPN Alpine Immune Sciences, Inc.
64.41
-0.04%